Company Overview

Maitreya Medicare Limited, incorporated in 2019 and based in Surat, Gujarat, is a specialized healthcare provider operating a 125-bedded, multispecialty hospital offering secondary and tertiary healthcare services. The company is listed and trades on the National Stock Exchange (NSE) under the symbol MAITREYA.

Business Model and Services

Maitreya Medicare Limited offers a comprehensive range of healthcare services across over 18 specialties and super specialties. These include:

- Cardiology

- Cardiothoracic and Vascular Surgery

- Critical Care Medicine

- Orthopedic and Joint Replacement Surgery

- Neurology & Neurosurgery

- Gastroenterology & Gastrointestinal Surgery

- Urology & Nephrology (including Dialysis)

- Oncology & Oncosurgery

- Gynecology & High-Risk Obstetrics

- Emergency and Trauma Care

- Spine Surgery

- Hepatocellular Billary Surgery

- General and Laparoscopic Surgery

The company was founded by Dr. Narendra Singh Tanwar, an experienced cardiologist with over 20 years in the healthcare industry, who serves as both the Chairman and Managing Director.

Financial Performance and Market Position

Market Capitalization and Valuation

- Market Cap: ₹196.47 Crore (as of June 10, 2025)

- Company Classification: Small Cap (Value Research)

- 1-Year Return: 105.93%

- Valuation Ratios:

- P/E (price-to-earnings) ratio: 104.51

- P/B (price-to-book) ratio: 6.47

- Book Value: ₹47.3

- Stock P/E: 101

- ROCE: 10.8%

- ROE: 6.57%

Financial Results

- FY Ended 2024: Profit of ₹3.17 crore on total income of ₹47.76 crore.

- Recent Consolidated Figures: Revenue of ₹46.7 Cr and Profit of ₹1.87 Cr.

- TTM Profit After Tax: ₹3 Cr.

- Trailing 12-Month Revenue: ₹70.71 Cr.

- Annual Revenue De-growth: -2%.

- Pre-tax Margin: 7%.

- ROE: 7%.

- Debt to Equity Ratio: 14% (indicating a healthy balance sheet).

Share Price Performance

- 52-Week High: ₹400.00

- 52-Week Low: ₹111.00

- Trading Range: ₹123.00 - ₹400.00

- Current Price: ₹280.00 (with significant volatility).

Shareholding Pattern and Corporate Governance

- Promoter Holding: 73.11% (as of Mar 2025), a slight decrease from 73.20% (as of Nov 2023).

- Promoter Pledging: None, which is a positive indicator.

- IPO Fund Utilization: The company reported no deviation in IPO fund use, with ₹1489.12 Lakh fully utilized as per prospectus for hospital and working capital.

- Financial Results Submission: Submitted financial results for the period ended March 31, 2025, on May 30, 2025.

Growth Prospects and Industry Position

- Patient Volume (FY2023): Served a total of 11,287 patients (7,208 OPD & diagnostics, 4,079 indoor services).

- Industry: Operates in India's rapidly expanding healthcare sector, benefiting from increased healthcare awareness and medical tourism.

- Quality Accreditation: NABH accredited, demonstrating commitment to quality.

- Management: Managed by an experienced and qualified professional team focused on providing cost-effective healthcare in under-served tier-2 and tier-3 cities.

Risk Factors and Challenges

- Supplier Dependency: Reliance on a limited number of suppliers for medicines and consumables could lead to increased procurement costs or supply shortages.

- Specialty Concentration: Heavy dependence on certain specialties (cardiology, neurology, orthopedics, general medicine) which contribute around 85% of total revenue, poses a risk if these services are negatively impacted.

- Dividend Policy: The company is not paying dividends, indicating profits are likely reinvested for business expansion and growth.

Maitreya Medicare represents a growing player in India's healthcare sector, with strong fundamentals and experienced management. Investors should carefully consider the concentration risks and competitive dynamics within the hospital industry.